# V1 Empirics Check — mistralai/mistral-large-2512 (Variant A)

**Model:** mistralai/mistral-large-2512
**Variant:** A
**Date:** 2026-04-08T09:47:57.496433

---

### 1. Idea Fidelity

The paper adheres closely to the original idea manifest, successfully executing the proposed **geology × policy interaction DiD** identification strategy. Key elements from the manifest are preserved:

- **Policy variation**: The 11 states with staggered RRNC adoption (1995–2021) are correctly identified, including the distinction between statewide and EPA Zone 1-only mandates.
- **Outcome data**: CDC WONDER mortality data is used (though the paper relies on state-level *all-cancer* mortality rather than county-level *lung cancer* mortality, likely due to data access constraints).
- **Geological variation**: The USGS GRP shapefile is employed to classify counties into high/low radon potential, with the interaction term (`Post_RRNC × HighGRP`) central to the analysis.
- **Identification strategy**: The triple-difference design and Callaway-Sant’Anna estimator for staggered adoption are implemented as promised.

**Deviations from the manifest**:
1. **Outcome granularity**: The manifest specifies county-year lung cancer mortality, but the paper uses state-year *all-cancer* mortality. This is a significant limitation (addressed below) but justified by data availability.
2. **Sample period**: The manifest covers 1999–2020, while the paper uses 1999–2017, likely due to lags in CDC data release.
3. **Secondary outcomes**: The manifest mentions radon testing rates and building permits, but these are not analyzed in the paper.

**Verdict**: The paper faithfully pursues the core idea, with deviations that are reasonable given data constraints.

---

### 2. Summary

This paper evaluates whether state-level Radon-Resistant New Construction (RRNC) building codes reduce cancer mortality by exploiting staggered adoption across 11 U.S. states and geological variation in radon potential. Using a triple-difference design (RRNC × high geological radon potential) and CDC state-level mortality data (1999–2017), the authors find **no statistically significant effect** on age-adjusted cancer death rates. The null result is robust to alternative specifications, placebo tests, and heterogeneity-robust estimators. The authors argue that the lack of detectable effects reflects the **long latency of radon-induced lung cancer** (15–25 years) and **slow housing stock turnover**, implying that RRNC benefits may take decades to materialize.

---

### 3. Essential Points

The paper is methodologically sound and transparent, but **three critical issues** must be addressed before publication:

#### **1. Outcome Measurement: All-Cancer vs. Lung Cancer Mortality**
- **Problem**: The paper uses *all-cancer* mortality (ICD-10 C00–C97) as the primary outcome, but radon exposure is linked *only* to lung cancer (C33–C34). Lung cancer accounts for ~25% of all cancer deaths, so any true effect is diluted by 75%.
- **Consequence**: The minimum detectable effect (MDE) of 4.5 deaths per 100,000 is **far larger** than plausible effects. For example, a 2-death reduction in lung cancer would appear as 0.5 deaths in all-cancer rates—well below the MDE.
- **Solution**:
  - **Justify the attenuation**: Explicitly state that the MDE for *lung cancer* would be ~1.1 deaths per 100,000 (4.5 × 0.25), which is still large but more interpretable.
  - **Acknowledge the limitation**: The null result could reflect either (a) no effect or (b) an effect too small to detect given attenuation. The paper should clarify that it cannot distinguish between these two.
  - **Future work**: Note that restricted-access CDC data (e.g., county-level lung cancer mortality) would resolve this issue.

#### **2. Power and Effect Size Interpretation**
- **Problem**: The power analysis (Section 4.3) is rigorous but underemphasizes the **policy-relevant effect size**. The EPA estimates that radon causes ~21,000 lung cancer deaths annually (~6.4 per 100,000). If RRNC codes reduce exposure by 50% in new homes (which constitute ~30% of the housing stock by 2017), the maximum plausible effect is ~1.9 deaths per 100,000 (6.4 × 0.5 × 0.3 × 0.25). This is **below the MDE of 4.5**.
- **Consequence**: The null result is **uninformative about policy efficacy**—it only rules out implausibly large effects.
- **Solution**:
  - **Reframe the conclusion**: The paper should state that the analysis **cannot detect realistic short-run effects** due to latency and stock turnover, rather than implying that RRNC codes are ineffective.
  - **Simulate power**: Show how power changes with longer post-adoption periods (e.g., 30–40 years) to illustrate when effects might become detectable.

#### **3. Geological Radon Potential (GRP) as a Dose Instrument**
- **Problem**: The paper treats GRP as an exogenous "dose" for RRNC effectiveness, but **GRP is correlated with state adoption decisions**. High-GRP states are more likely to adopt RRNC codes (Figure 5), which could bias the triple-difference estimate if unobserved confounders (e.g., health infrastructure) also correlate with GRP.
- **Consequence**: The triple-difference estimate (`Post_RRNC × HighGRP`) may reflect **selection bias** rather than a true dose-response relationship.
- **Solution**:
  - **Test for pre-trends by GRP**: Show event-study plots separately for high- and low-GRP states to confirm parallel trends *within* the treated group.
  - **Instrument for GRP**: Use geological features (e.g., uranium content in bedrock) that are plausibly exogenous to modern policy choices but predictive of GRP.
  - **Discuss selection**: Acknowledge that GRP is not fully exogenous and interpret the triple-difference results as **descriptive** rather than causal.

---

### 4. Suggestions

#### **A. Strengthening the Identification Strategy**
1. **County-level analysis**:
   - If possible, use **county-level lung cancer mortality** (available via CDC WONDER restricted data or SEER) to avoid attenuation bias. This would also allow for **within-state variation** in GRP, improving power.
   - If county data is unavailable, consider **synthetic control methods** for states with long post-adoption periods (e.g., NJ, WA).

2. **Alternative dose measures**:
   - Replace the binary `HighGRP` indicator with **continuous measures** (e.g., mean indoor radon levels from EPA testing data) to better capture dose-response.
   - Use **uranium concentration in bedrock** (from USGS geochemical surveys) as an instrument for GRP to address endogeneity.

3. **Dynamic effects**:
   - Extend the event study to **longer post-adoption periods** (e.g., 20+ years) to test whether effects emerge over time. The current event study (Figure 2) only shows 5–6 years post-adoption for most states.

#### **B. Improving Interpretation**
1. **Cost-benefit analysis**:
   - Expand the back-of-the-envelope calculation (Section 5.6) to compare:
     - **Short-run costs**: \$350–\$500 per new home × annual new construction.
     - **Long-run benefits**: Projected lung cancer deaths averted using EPA risk models and housing stock turnover rates.
   - This would clarify whether RRNC codes are **cost-effective despite delayed benefits**.

2. **Policy implications**:
   - Discuss whether **mandatory radon testing at point-of-sale** (e.g., during home sales) might yield faster health benefits than RRNC codes, given the slow stock turnover.
   - Compare RRNC to **other radon policies** (e.g., EPA’s Zone 1 designations, public awareness campaigns) in terms of cost and effectiveness.

3. **External validity**:
   - Acknowledge that the 11 adopting states are **not representative** of the U.S. (e.g., higher GRP, stronger building codes). Discuss whether results generalize to low-GRP states.

#### **C. Robustness Checks**
1. **Alternative GRP definitions**:
   - Test thresholds other than 50% (e.g., 30%, 70%) for the `HighGRP` indicator.
   - Use **county-level GRP** (instead of state-level) in a county-year analysis if data permits.

2. **Placebo tests**:
   - Add **placebo GRP interactions** (e.g., `Post_RRNC × Placebo_GRP`, where Placebo_GRP is a random reassignment of GRP scores) to confirm that the triple-difference result is not spurious.

3. **Heterogeneity by adoption timing**:
   - Split the sample into **early adopters** (NJ, WA) and **late adopters** (2009+) to test whether effects emerge with longer exposure.

#### **D. Data and Transparency**
1. **Reproducibility**:
   - Provide **code and data** (e.g., via GitHub) to replicate the analysis, including:
     - GRP county assignments (with nearest-province fallback).
     - RRNC adoption dates and scope (statewide vs. Zone 1).
   - Clarify how **population weights** are constructed (e.g., are they based on total population or housing stock?).

2. **Visualization**:
   - Add a **map of RRNC adoption by state** (similar to Figure 1) to help readers contextualize the policy variation.
   - Overlay **GRP and RRNC adoption** in a single figure to show the correlation between geology and policy.

3. **Appendix**:
   - Include a **table of RRNC code details** (e.g., specific requirements, enforcement mechanisms) for each state.
   - Add a **power simulation** showing how detectable effect sizes change with longer post-adoption periods.

#### **E. Framing and Motivation**
1. **Novelty**:
   - Emphasize that this is the **first quasi-experimental evaluation** of RRNC codes, contrasting it with prior cross-sectional or ecological studies (e.g., Turner et al., 2011).
   - Highlight the **generalizability** of the geology × policy framework to other regulations (e.g., flood-resistant construction, earthquake retrofits).

2. **Latency discussion**:
   - Compare the **latency of radon-induced lung cancer** (15–25 years) to other environmental health interventions (e.g., air pollution, lead abatement) to contextualize the null result.
   - Cite **Almond (2009)** on Chernobyl’s long-term cognitive effects to illustrate how delayed effects can emerge decades later.

3. **Policy relevance**:
   - Discuss why **short-run evaluations** of long-latency policies are common (e.g., political pressure, funding cycles) and how this paper’s null result underscores the need for **longer evaluation horizons**.
   - Suggest **intermediate outcomes** (e.g., indoor radon levels, radon testing rates) that could be used to evaluate RRNC codes in the short run.

---

### Final Assessment

This is a **rigorous and transparent** paper that makes a valuable contribution to the literature on environmental health policies and building codes. The null result is **credibly estimated** and robust to multiple specifications, but the **outcome measurement and power limitations** prevent strong conclusions about policy efficacy. With the suggested revisions—particularly around **lung cancer specificity, power interpretation, and GRP endogeneity**—the paper would be suitable for publication in a field journal (e.g., *Journal of Health Economics*, *Journal of Environmental Economics and Management*).

**Recommendation**: Revise and resubmit, with particular attention to the three essential points above. The core identification strategy is sound, and the paper’s transparency about limitations is a strength. The revisions should focus on **clarifying what the null result does (and does not) imply** about RRNC codes.
